Background
Methods
Study design and sampling
Tissue micro array construction (TMA)
Immunohistochemistry
Antibody | Clone | Source | Antigen retrieval | Dilution |
---|---|---|---|---|
CD3 | SP7 | Immunotech | EDTA 750 W | 1:250 |
CD5 | 54/F6 | Dako | EDTA 900 W | 1:10 |
CD10 | 56C6 | Novocastra | EDTA 900 W | 1:5 |
CD20 | L26 | Dako | EDTA 750 W | 1:200 |
CD23 | 1B12 | Novocastra | EDTA 900 W | 1:30 |
CD30 | Ber- H2 | Prof. Falini * | EDTA 900 W | 1:3 |
CD38 | SPC32 | Novocastra | EDTA 750 W | 1:10 |
CD79a | JCB117 | Prof. Mason § | EDTA 750 W | 1:10 |
CD138 | - | Neomarkers | EDTA 900 W | 1:20 |
BCL-1 | SP4 | Neomarkers | EDTA 900 W | 1:20 |
BCL-6 | PG-B6p | Prof. Falini * | EDTA 900 W | Undiluted |
BCL-2 | 124 | Prof. Mason§ | EDTA 900 W | 1:3 |
IRTA-1 | Mum2EC | Prof. Falini * | EDTA 900 W | 1:2 |
MUM1/IRF4 | - | Prof. Falini * | EDTA 900 W | 1:2 |
TdT | - | Dako | None | 1:30 |
ALKc | - | Prof. Falini * | EDTA 900 W | 1:2 |
Ki-67 | Mib-1 | Dako | EDTA 900 W | 1:20 |
Data management, analysis and statistical issues
Ethical issues
Study limitations
Results
Background characteristics
Diagnosis | ||||
---|---|---|---|---|
Marker | Burkitt lymphoma (%positive) | Diffuse large B cell lymphoma (% positive) | Precursor B lymphoblastic lymphoma | Mantle cell lymphoma |
CD10 | 74/79(93.7) | 3/18 (16.7) | 1/1 | 0/4 |
CD20 | 95/95(100) | 19/19(100) | 1/1 | 4/4 |
BCL6 | 46/69(66.7) | 2/19(10.5) | 0/1 | 1/4 |
CD79a | 48/68(70.6) | 6/16(37.5) | 1/1 | 2/4 |
CD38 | 35/68(51.5) | 3/16(18.8) | 0/1 | 0/4 |
MUM-1/IRF4 | 1/77(1.3) | 4/18(22.2) | 0/1 | 0/4 |
EBER | 79/86(91.9) | 6/17(35.3) | 1/1 | 0/4 |
Tdt | 0/95(0) | 0/19(0) | 1/1 | 0/4 |
BCL2 | 6/79(7.6) | 7/19(36.8) | 1/1 | 4/4 |
CD3 | 0/86(0) | 0/19(0) | 0/1 | 0/3 |
CD138 | 43/95(45.3) | 10/15(66.7) | 0/1 | 4/4 |
CD30 | 35/95(36.8) | 2/17(11.8) | 0/1 | 0/4 |
Burkitt lymphoma survival
Variable | Hazard's ratio (95.0% CI) | p value |
---|---|---|
Received chemotherapy | 0.15 (0.001-0.195) | 0.001 |
CD30 | 0.427 (0.098-1.863) | 0.257 |
Male | 4.207 (0.775-22.84) | 0.096 |